163 related articles for article (PubMed ID: 17106751)
1. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
2. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
3. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
4. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
Mulders TM; Keizer ; Ouwerkerk J; van der Velde EA; Breimer DD; Mulder GJ
Clin Cancer Res; 1995 Dec; 1(12):1525-36. PubMed ID: 9815953
[TBL] [Abstract][Full Text] [Related]
5. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
7. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Brüggemann SK; Pfäffle S; Peters SO; Wagner T
Drug Metab Dispos; 2007 Oct; 35(10):1721-4. PubMed ID: 17600085
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
9. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.
Brain EG; Rezai K; Lokiec F; Gutierrez M; Urien S
Br J Clin Pharmacol; 2008 Apr; 65(4):607-10. PubMed ID: 18294323
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
[TBL] [Abstract][Full Text] [Related]
17. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
19. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
20. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
